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1004-47 A Randomized Comparison of Transradial and 
Transfemoral Approaches for Coronary Angiography 
and Percutaneous Transluminal Coronary Angioplasty 
in Octogenarians: Final Results of the OCTO-PLUS 
Study
Yves Louvard, Rémi Sabatier, Hakim Benamer, Philippe Garot, David Hildick-Smith, 
Christophe Loubeyre, Thierry Lefèvre, Gilles Grollier, Martial Hamon, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: The rate of access site complications after coronary angiography (Angio)
and/or PCI has been shown to be higher in older patients. This prospective randomized
study was carried out to assess the potential advantages of Transradial (TRA) approach
in this setting.
Methods: Patients (pts) undergoing Angio or PCI were randomized to either transfemoral
approach (TFA) or TRA in 5 centers using TRA in routine. The primary end-point was the
rate of access site complications leading to increased hospital stay.
Results: Study population included 371 pts, mean age 82.8 + 2.9 years, 53.4 % male,
presenting with unstable angina in 35.6% of cases or AMI in 10.5%. 188 pts were ran-
domized to TRA (174 angio followed by 87 PCI, and 9 PCI), 183 to TFA (176 angio fol-
lowed by 74 PCI and 12 PCI). 51.9% of PCI pts received a femoral closure device. Main
results by intention to treat are summarized below: 
* per protocol: 0.5% vs 7.6%, p= 0.001
Conclusion: Combined end-point of all approach-related vascular complications leading
to prolonged hospital stay is significantly lower in octogenarians randomized to transra-
dial approach for coronary angiography and/or PCI compared to transfemoral approach.
As in younger patients, for coronary angiography, X-Ray exposure time is slightly but sig-
nificantly longer in the transradial group. There is no difference in X-Ray exposure time
for PCI, procedural time, contrast medium volume and equipment use in Angio and PCI.
1004-48 Randomized Trial of Radial Versus Femoral Access for 
Primary and Rescue Angioplasty
Warren J. Cantor, Geoff Puley, Madhu Natarajan, Vlad Dzavik, Mina Madan, Anne Fry, 
Nurry Pirani, Hahn Hoe Kim, James Velianou, Bradley H. Strauss, Robert J. Chisholm, 
St. Michael's Hospital, Toronto, ON, Canada
Background: Transradial access for percutaneous coronary intervention (PCI) results in
fewer bleeding and vascular complications, earlier ambulation and improved patient com-
fort. Limited data exists for radial access in acute myocardial infarction (MI), where reper-
fusion must occur quickly.
Methods: In a multicentre pilot trial, 50 patients with MI requiring either primary or res-
cue PCI were randomized to radial or femoral access. Patients in cardiogenic shock were
excluded. All patients received aspirin and heparin. All operators had previously per-
formed at least 100 transradial cases. Procedure times were prospectively measured. All
patients underwent ultrasound-Doppler of the access site, and were followed to 30 days.
Results: To date, procedural data, inhospital events and Doppler results are available for
44 patients (25 radial, 19 femoral). Thrombolysis was used in 68% of cases and glyco-
protein IIb/IIIa inhibitors were used in 91%. Crossover from radial to femoral access was
required in one case. PCI was performed in 41 patients, with stenting in 39. One proce-
dural failure occurred in the radial group due to inability to cross the occlusion. The time
from local anaesthesia to first balloon inflation was 32 (26, 38) min for radial and 25 (22,
30) min for femoral access (p=0.04). There were no significant differences in contrast use
or fluoroscopy time. No patients required intra-aortic balloon pump. No patients experi-
enced major bleeding or required transfusions. By Doppler there were two asymptomatic
radial occlusions and two pseudoaneurysms (one in each group). There were no strokes,
reinfarctions, vascular surgeries, bypass or repeat PCI. One patient in the femoral group
died two days after PCI. Outcomes at 30 days and quality of life data will be presented.
Conclusions: Transradial access for primary or rescue PCI is feasible with high success
rates similar to femoral access. Although radial access was associated with a longer time
to reperfusion, the difference was small and likely not clinically significant. In patients
without shock, major bleeding and vascular complications are infrequent with either
access site despite the high use of thrombolysis and GP IIb/IIIa inhibitors.
1004-49 The Risk of Bleeding in Renal Failure Patients 
Undergoing Glycoprotein IIb/IIIa Receptor Inhibition: A 
Report From the American College of Cardiology-
National Cardiovascular Data Registry
Hursh S. Naik, Peter Y. M. Hui, Rupsa R. Yee, Richard E. Shaw, American College of 
Cardiology National Cardiovascular Data Registry (ACC-NCDR), Bethesda, MD
Background: Renal dysfunction is present in a substantial number of patients undergo-
ing percutaneous coronary intervention (PCI). Few studies have investigated the effect of
Glycoprotein (Gp) IIb/IIIa inhibition in these patients. The purpose of this study was to
evaluate bleeding complications with Gp IIb/IIIa inhibitors in patients with renal failure.
Methods: Between January 1, 2001 and March 31, 2003 data from 278,105 consecutive
PCI procedures were submitted from 304 institutions to the American College of Cardiol-
ogy National Cardiovascular Data Registry (ACC-NCDR). Vascular bleeding events with
and without IIb/IIIa inhibitors were compared in patients with renal dysfunction using chi-
square analysis.
Results: Out of 278,105 patients in the ACC-NCDR registry, 12,059 patients had renal
failure. Renal failure was defined as a documented history of renal failure that was
treated with medication, low protein diet, or dialysis by a physician. In the absence of Gp
IIb/IIIa inhibition, patients with renal failure had more bleeding complications than those
without renal failure (2.8% vs. 1.9% p-value <0.0001). However, in the renal failure group
there was no significant increase in bleeding complications with or without the addition of
Gp IIb/IIIa inhibitors (2.4% vs. 2.8% p-value = ns).
Conclusion: The presence of renal dysfunction during PCI predisposes patients to
bleeding complications. This risk is not significantly increased with the addition of Gp IIb/
IIIa inhibitors. Therefore, Gp IIb/IIIa inhibition in the setting of renal dysfunction, does not
appear to be an independent risk factor for bleeding.
1004-50 Percutaneous Ulnar Artery Approach for Coronary 
Diagnostic and Therapeutic Interventions
Eduardo Aptecar, Patrick Dupouy, Mourad Chabane-Chaouch, Youssef Elhajj, Jean-Marc 
Pernès, Clinique Les Fontaines, Melun, France, Hôpital Privé d'Antony, Antony, France
Background: While the transradial approach is now a well established alternative to fem-
oral approach, the use of the ulnar artery has rarely been intended for percutaneous cor-
onary interventions (PCI).
Aim of the study: to ascertain the feasability and security of the transulnar approach for
PCI.
Methods: 143 consecutive patients referred for PCI were screened, and were eligible if a
good ulnar pulse was present and if the Allen test was positive. The right ulnar artery was
punctured with a 20-gauge x 2” entry needle, into which a straight 0.025” guide wire was
inserted (Radifocus Introducer II, Terumo). A 4 F introducer was placed on the wire.
Sodium heparin (3,000 IU) and verapamil (2.5 mg) were injected. Coronary arteries and
left ventricle were catheterized with 4 F JL4 and JR4 or AL2, and pig-tail catheters.
Angioplasty was made using 5 or 6 F guiding catheters. Manual compression was done
after retrieval of the introducer. An Echo Doppler of the wrist vessels was done 10 + 7
days after procedure.
Results: from 143 patients screened, ulnar access was intended in 107 pts (73%), suc-
cessful in 96 pts (91%). Time and number of ponctions were 118 ± 135 sec and 1,6
(maximal 5). 
There were no procedural complications. Echo Doppler was obtained in 91 pts (94%).
Access site complications were: 0 occlusion, 1 pseudo-anevrysm, 3 slight hematomas.
Conclusion : ulnar artery approach is a feasible and safe alternative to radial approach
for percutaneous coronary interventions.
1004-51 Assessment of the Feasibility, Safety, and Success of 
Transradial Access for Percutaneous Coronary 
Intervention: A Report From the American College of 
Cardiology-National Cardiovascular Data Registry
Ahmed S. Ahmed, Mohammed Murtaza, Timothy Catchings, Richard Webel, Ba Lin, 
Richard Shaw, Greg C. Flaker, University of Missouri-Columbia, Columbia, MO, The 
American College of Cardiology, Bethesda, MD
Background: Previous studies have shown that transradial access (TRA) appears to be
safe, with an acceptable success rate, but these studies were limited by small sample
size. The purpose of this study was to evaluate the feasibility, safety and success rate of
the TRA for percutaneous coronary intervention (PCI) in contemporary practice. Meth-
ods: Between January 1, 2001 and March 31, 2003, data on 278,105 PCI procedures
were submitted from 304 institutions to the American College of Cardiology National Car-
diovascular Data Registry (ACC-NCDR). Of these, valid data on access site entry were
available for 275,290 PCI procedures. TRA was used in 3,237 (1.2%) of these proce-
Radial P value Femoral
Cross-over (%) 9.0 ns 8.2
Angio duration (min 18.5±10.5 0.069 16.4±11.0
X-ray duration (min) 6.0±4.4 0.01 4.4±3.4
PCI success (%) 95.3 ns 93.7
PCI duration (min) 33.9±21.6 ns 34.1±23.1
PCI X-ray duration (min) 11.5±9.5 ns 10.8±9.9
Primary endpoint* 1.6 0.03 6.6
Hematoma>3 cm (%) 2.2 0.0025 11.4




X-ray time X-ray dose
% (min) (min) (Gycm2)
Coronarography 71 100 13,2 + 5,2 7,1 + 3,5 35 + 27
Coronarography + 
PTCA
20 100 41+ 26 19,4 + 14 126 + 70
DelayedPTCA 5 100 25 + 16 13 + 7 74 + 38
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dures. Results: Compared to Non-TRA, TRA was used more commonly in males (70.5%
vs. 65.7%; p<0.0001), but less often in hypertensives (65.7% vs. 69.2%; p<0.0001),
patients with a history of renal failure (3.0% vs. 4.3%; p<0.0001), patients with prior MI
(25.8% vs. 28.6%; p<0.0001) or prior coronary artery bypass graft surgery (11.6% vs.
19.1%). TRA patients were significantly younger (61±12 vs. 63±12 years; p<0.0001) and
more likely to have BMI > 35 (20.1% vs. 16.1%; p<0.0001). Mortality risk was signficantly
lower in TRA patients (0.6% vs. 1.2%; p<0.00001) compared to Non-TRA patients.
Adjusted mortality (observed/expected X observed) was similar between the groups, as
was PCI success. Patients with TRA had a length of hosptial stay 0.5 days shorter than
Non-TRA patients (p<0.0001). Bleeding was less common with TRA (0.7% vs. 1.7%;
p<0.0001) and both males and females had singifncantly less bleeding (0.4% vs. 1.1%
for males, and 1.4% vs. 2.8% for females; both p<0.0001). Multivariate analysis demon-
strated that TRA was idependently associated with less bleeding complications. Conclu-
sions The transradial access is more likely to be used in less severely ill patients, but
outcomes are comparable and there does appear to be less bleeding, both for males and
females.
1004-52 Impact of Abciximab on Distal Embolization Induced by 
Primary Angioplasty
Ugo Limbruno, Marco De Carlo, Sabina Pistolesi, Giovanni Amoroso, Tiziano Camacci, 
Gabriella Fontanini, Nicola Ciabatti, Daniele Carbocci, Giorgio Riccetti, Anna S. Petronio, 
Mario Mariani, University of Pisa, Pisa, Italy
Background. Distal embolization during primary angioplasty (PA) may affect myocardial
reperfusion. We evaluated the impact of Abciximab pre-treatment on the entity and quali-
tative composition of PA-induced distal embolization. Methods. Fourty-two consecutive
patients with acute myocardial infarction underwent PA using the non-occlusive distal
protection device FilterWire Ex (Boston Scientific Corp., USA). Abciximab pre-treatment
was performed in 22 patients (52%). The embolic fragments retrieved from the filters
underwent morphometric and histopathological analysis. Serial histological sections (5
micron intervals) were stained with hematoxylin-eosin. Additional histochemical stains
were: Weigert for fibrin, Oil Red-O for lipid droplets, Alcian blue for mucopolisaccharides,
anti M-CSF monoclonal antibodies for macrophages, and anti collagen monoclonal anti-
bodies for collagen fibers. The total debris area was calculated for each patient. Results.
Particles were recovered in 37 out of 42 devices (88%). Abciximab administration did not
significantly reduce number and size of the particles with respect to the control group
(mean number: 21±17 vs 22±27, P=NS; total debris area: 3.7±4.8 vs 3.6±6.0 mm*mm,
P=NS). Particles of fresh thrombus containing fibrin, platelets, and red cells were
observed in 4 abciximab patients and in 5 control patients (20% vs 29%, P=NS); plaque
fragments in 5 and 4 patients (25% vs 24%, P=NS)and partially organized thrombus par-
ticles 11 and 8 patients (55% vs 47%, P=NS). Among clinical and angiographic variables,
only the angiographic signs of high thrombus burden (a cut-off pattern or a minus image
greater than 3 times the reference lumen diameter)were significantly related to the total
debris area at multivariate analysis. Conclusion. Distal embolization occurs in the vast
majority of patients undergoing PA and often incorporates plaque-containing debris and
partially organized clots, which are probably unresponsive to anti-platelet drugs. Accord-
ingly, abciximab pre-treatment does not appear to reduce the embolic burden.
1004-53 Adjunctive Pharmacotherapy During Higher Risk 
Percutaneous Coronary Intervention: Eptifibatide-
Based Antiplatelet Therapy Accompanied by Only 
Limited, Specific Antithrombin Therapy
Scott J. Denardo, Keith E. Davis, James E. Tcheng, FirstHealth of Carolinas/Moore 
Regional Hospital, Pinehurst, NC, Duke University Medical Center, Durham, NC
Background. Adjunctive pharmacotherapy during higher risk percutaneous coronary
intervention (PCI) has historically consisted of a combination of anti-platelet and anti-
thrombin drugs. However, anti-platelet drugs such as eptifibatide that block the glycopro-
tein IIb/IIIa receptor have been shown in-vitro to prevent both platelet aggregation and
thrombin generation. We therefore hypothesized that, for higher risk PCI, eptifibatide-
based anti-platelet therapy accompanied by only limited, specific anti-thrombin therapy
would be efficacious and safe. Methods. In this observational study, we retrospectively
assessed the outcomes of 786 consecutive inpatients (pts) undergoing urgent, higher
risk PCI for treatment of either unstable angina (535 pts), acute pulmonary edema (67
pts), or acute, non-ST segment elevation myocardial infarction (184 pts). PCI techniques
included stent deployment, cutting balloon atherotomy, high speed rotational atherec-
tomy, and conventional balloon angioplasty. The 786 pts received adjunctive pharmaco-
therapy consisting of the anti-platelet drugs aspirin, clopidogrel (at least 300 mg net dose
prior to PCI), and eptifibatide (double bolus at time of PCI), and a reduced final dose of
the anti-thrombin drug enoxaparin (administered prior to PCI, as part of routine care for
initially presenting problem). Pts received no other scheduled, specific anti-thrombin ther-
apy. Results. Pts received as their final enoxaparin dose, on average, 0.51 mg/kg subcu-
taneously, 7.8 hours prior to PCI. The technical success rate for PCI was 99.6%. During
the first 24 hours following PCI, there was one major adverse event (0.1%). The inci-
dence of non-Q wave myocardial infarction was 1.8%. The incidences of major and minor
bleeding complications were 0.2% and 1.8%, respectively, and the incidence of thromb-
ocytopenia was 1.4%. During the subsequent 30 days following PCI, there were four
major adverse clinical events (0.5%). Conclusions. For higher risk PCI, eptifibatide-based
anti-platelet therapy accompanied by only limited, specific anti-thrombin therapy appears
efficacious and safe.
1004-54 A Prospective Study to Evaluate Adequacy of 
Anticoagulation for Percutaneous Coronary 
Interventions in Patients With Acute Coronary 
Syndromes Presenting for Early Angiography on 
Subcutaneous Enoxaparin
Saihari Sadanandan, Faisal Latif, Balaji Veerappan, Christie E. Burgin, Sushmita 
Patibandala, Thomas Hennebry, Mohammad Ghani, Jorge Saucedo, Eliot Schechter, 
Kenneth Blick, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background: Current recommendations for PCI in subcutaneous enoxaparin (SQE)
treated acute coronary syndrome (ACS) pts are based on studies in which pts received
SQE for >2 days and a steady state may have been reached. Data on adequacy of anti-
coagulation for PCI in SQE treated pts presenting for early cardiac catheterization (cath)
are limited. Methods: We prospectively studied 77 ACS pts treated with SQE (1mg/kg
bid) who presented for cath <12 hrs from the last SQ dose. Pts were divided into two
groups based on number of doses of SQE received prior to cath, <2 doses (n=42) or >2
doses (n=35). Anti-Xa levels and ENOX clotting time (a novel point of care test for enox-
aparin) were measured in all pts during cath. An anti-Xa level of >0.8 IU/ml was consid-
ered as therapeutic anticoagulation for PCI. Additional IV enoxaparin during PCI was
given at the discretion of the physician. ENOX clotting time was correlated with anti-Xa
levels. Results: Baseline characteristics and medications were similar between the 2
groups. The median (IQ range) number of doses of SQE prior to cath in the <2 and > 2
doses group were 2.0 (1.0, 2.0) and 4.0 (3.0, 6.0) respectively. The median elapsed time
between last SQE and cath was 4.5 (3.0, 6.0) hrs in <2 doses group and 4.0 (2.0, 5.0) hrs
in >2 doses group (p=0.1). IV GP 2b/3a inhibitors use (45% vs. 43%, p=0.8) and PCI
rates (41% vs. 51%, p=0.3) were not different. Median anti-Xa level was 0.8 (0.6, 1.1) IU/
ml in <2 doses group and 1.0 (0.8, 1.3) IU/ml in > 2 doses group (p=0.05). The % of pts
with anti-Xa <0.8 IU/ml was 43% in <2 doses group compared with 20% in >2 doses
group (p=0.033). Overall 29% of pts in both groups received additional anticoagulation in
the cath lab. In-hospital death (2.4 vs. 0%), MI (4.8 vs. 2.9%), urgent TVR (2.4% vs. 0%),
and major bleeding (2.4 vs. 2.9%) were not significantly different between the groups.
The overall correlation between ENOX clotting time and anti-Xa levels was modest
(r=0.5, p<0.001). However, 85% of pts with ENOX clotting time >250s had anti-Xa levels
>0.8 IU/ml. Conclusions: ACS pts on SQE presenting early for cath have lower median
anti-Xa levels and frequently have anti-Xa levels <0.8 IU/ml. Most pts with ENOX clotting
time of >250s at cath have anti-Xa levels >0.8 IU/ml.
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1005-41 Percutaneous Endovascular Reconstruction for Chronic 
Occlusions in Peripheral Vascular Disease: A Quality of 
Life Perspective
Eric J. Dippel, Nicolas W. Shammas, Vickie S. Takes, Lauren E. Coyne, Jon H. Lemke, 
Genesis Medical Center, Davenport, IA
Background: Guidelines for the management of peripheral vascular disease (PVD) rec-
ommend surgical revascularization for superficial femoral artery (SFA) chronic total
occlusions (CTO) >5cm (TASC Type D lesions)[1]. We report our experience on the tech-
nical feasibility and impact on quality of life using standard stenting techniques to treat
“surgical disease” of the lower extremities.
Methods: We reviewed our database for patients that underwent percutaneous revascu-
larization for SFA CTO. Traditional primary stenting techniques were employed utilizing
the self-expanding, nitinol SMART® stent (Cordis, Miami, FL). The Walking Impairment
Questionnaire[2] (WIQ range: 0 to 14,080) was used to assess quality of life pre and post
procedure. Ankle-brachial index (ABI) was obtained pre and post procedure.
Results: 44 patients (51 legs) underwent attempted percutaneous revascularization for
SFA CTO TASC Type D lesions at Genesis Medical Center, Davenport, IA, USA between
August 2000 and July 2003. Successful revasc 90.2%, Ave CTO length (cm) 15.5 + 9.9,
Ave stent length (cm) 23.2 + 12.2, Min stent diam (mm) 7.0 + 0.6, Min artery diam (mm)
5.9 + 0.6, Stents deployed 2.7 + 1.7; Pre-WIQ 722 + 1503, Post-WIQ 8421 + 5741
(p<0.0005), Median delta-WIQ 7405 (95% CI: 6555 to 9245); Pre-ABI 0.61 + 0.18, Post-
ABI 0.91 + 0.19 (p<0.0005) , Median delta-ABI 0.27 (95% CI: 0.21 to 0.33); Median fol-
low-up (days) 374 + 321; Repeat revasc: PTA 13.7%, surgery 3.9%, Amputation 2.0%;
Death (at follow up) 6.8%
Conclusions: Traditional “surgical disease” can be treated with a high degree of success
by standard angioplasty and nitinol stenting techniques. Patients have a significant
improvement in their quality of life, and objective improvement on serial non-invasive test-
ing. Repeat revascularization rates are reasonably low, and parallel historical surgical
data. A minimally invasive percutaneous approach should become the initial preferred
method of revascularization for lower extremity PVD regardless of the TASC lesion type.
[1] TransAtlantic Inter-Society Consensus Statement. J of Vasc Surg (suppl). Jan
2000;31(1):S1-S296.
[2] Circulation. 1995;92:614-21.
